Sign Out
Posology: Recommended dose: 550 mg twice a day. The clinical benefit was established from a controlled study in which subjects were treated for 6 months. Treatment beyond 6 months should take into consideration the individual balance between benefits and risks, including those associated with the progression of hepatic dysfunction (see Precautions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
REFERO can be administered with or without food.
Paediatric population: The safety and efficacy of REFERO in paediatric patients (aged less than 18 years) have not been established.
Elderly: No dosage adjustment is necessary as the safety and efficacy data of REFERO showed no differences between the elderly and the younger patients.
Hepatic impairment: No dosage adjustment is necessary for patients with hepatic insufficiency (see Precautions).
Renal impairment: Although dosing change is not anticipated, caution should be used in patients with impaired renal function (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: Orally with a glass of water.
Continue with Google